| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 1, 2023
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference: SVB...
-
Jan 26, 2023
For the first time ever, a demonstration version of one of Recursion's Compound Intelligence tools to explore maps of biology and chemistry is open for anyone to use RxRx3, the underlying dataset...
-
Dec 20, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences: 41st...
Nov 8, 2022Initiated our Phase 2 clinical trial for the potential treatment of familial adenomatous polyposis (FAP) Initiated our Phase 1 clinical trial for the potential treatment of Clostridium difficile...
-
Nov 2, 2022
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conferences:...